Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders

Annals of Neurology

Volumn 56, Issue 3, 2004, Pages 416-423

  Letendre, Scott L ^a,b   McCutchan, J Allen ^a,b   Childers, Meredith E ^a,c   Woods, Steven P ^a   Lazzaretto, Deborah ^a   Heaton, Robert K ^a   Grant, Igor ^a   Ellis, Ronald J ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG PENETRATION; EVALUATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 4444273727     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20198     Document Type: Article

References (58)

1. Rabkin JG, Chesney MA. Adhering to complex regimens for HIV. GMHC Treat Issues 1998;12:8-11.
2. Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 2002;59:1944-1950.
3. Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004;10:317-331.
4. Ellis RJ, Deutsch R, Heaton RK, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. Arch Neurol 1997;54:416-424.
5. Strain MC, Letendre S, Pillai S, et al. Genetic composition of HIV-1 in CSF and plasma without treatment and during failing combination antiretroviral therapy. J Virol (in press).
6. Ellis RJ, Moore DJ, Childers ME, et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 2002;59: 923-928.
7. Marra CM, Lockhart D, Zunt JR, et al. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology 2003;60:1388-1390.
8. Robertson KR, Robertson WT, Ford S, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 2004;36:562-566.
9. Woods SP, Rippeth JD, Frol AB, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol (in press).
10. Heaton R, Kirson D, Velin R, et al. The utility of clinical ratings for detecting early cognitive change in HIV infection. In: Grant I, Martin A, eds. Neuropsychology of HIV infection. New York: Oxford University Press, 1994:188-206.
11. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scotes for detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol (in press).
12. Heaton RK, Grant I, Butters N, et al. The HNRC 500-neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1995;1:231-251.
13. CDC 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41: 1-19.
14. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44:920-928.
15. Letendre SL, Capparelli EV, Ellis RJ, et al. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group. Antimicrob Agents Chemother 2000;44:2173-2175.
16. Letendre S, Ellis R, Grant I, et al. The CSF concentration (conc)/IC50 ratio: a predictor of CNS antiretroviral (ARV) efficacy (abstract K1004p). Eighth Conference on Retroviruses and Opportunistic Infections; 2001; San Francisco.
17. Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002;16: 595-609.
18. Tashima KT. Cerebrospinal fluid levels of antiretroviral medications: abstract and commentary. JAMA 1998;280: 879-880.
19. Zhou XJ, Havlir DV, Richman DD, et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 2000;14:2869-2876.
20. Burger DM, Kraaijeveld CL, Meenhorst PL, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993;7:1581-1587.
21. Rolinski B, Bogner JR, Sadri I, et al. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:192-197.
22. Masereeuw R, Jaehde U, Langemeijer MW, et al. In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors. Pharm Res 1994; 11:324-330.
23. Haworth SJ, Christofalo B, Anderson RD, et al. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:235-238.
24. van Praag RM, Weverling GJ, Portegies P, et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000;14:1187-1194.
25. McDowell JA, Chittick GE, Ravitch JR, et al. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999;43:2855-2861.
26. Foudraine NA, Hoetelmans RM, Lange JM, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998;351:1547-1551.
27. Capparelli EV, Letendre S, Ellis R, et al. Population pharmacokinetic-based estimation of abacavir (ABV) CSF penetration. Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego.
28. van Praag RM, van Weert EC, van Heeswijk RP, et al. Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother 2002;46:896-899.
29. Yazdanian M, Ratigan S, Joseph D, et al. Nevirapine, a nonnucleoside rt inhibitor, readily permeates the blood-brain barrier. 4th Conference on Retroviruses and Opportunistic Infections. 1997; Washington, DC.
30. Prins J, Van Praag R, Jurriaans S, et al. Drug levels and HIV-1 RNA in serum and CSF during treatment with a five-drug regimen: AZT, 3TC, Abacavir, Nevirapine (NVP), and Indinavir (IDV). 7th Conference on Retroviruses and Opportunistic Infections; 2000; San Francisco.
31. Kearney B, Price R, Sheiner L, et al. Estimation of nevirapine exposure within the cerebrospinal fluid using CSF:plasma area under the curve ratios. 6th Conference on Retroviruses and Opportunistic Infections; 1999; Chicago, IL.
32. Norusis M. SPSS Advanced Statistics 6.1. Chicago: SPSS Inc., 1994:606.
33. JMP User's Guide Version 3.1 of JMP. Cary, NC: SAS Institute Inc., 1995:239.
34. Sacktor N, Skolasky RL, Tarwater PM, et al. Response to systemic HIV viral load suppression correlates with psychomotor speed performance. Neurology 2003;61:567-569.
35. Antinori A, Giancola ML, Grisetti S, et al. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS 2002;16: 1867-1876.
36. Ellis RJ, Gamst AC, Capparelli E, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 2000;54:927-936.
37. Ohagen A, Devitt A, Kunstman KJ, et al. Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol. 2003;77:12336-12345.
38. Petito CK. Human immunodeficiency virus type 1 compartmentalization in the central nervous system. J Neurovirol 2004; 10(suppl 1):21-24.
39. Wong JK, Ignacio CC, Torriani F, et al. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 1997;71:2059-2071.
40. Smith A. Symbol Digit Modalities Test. Los Angeles: Western Psychological Services, 1991.
41. Wilkie FL, Eisdorfer C, Morgan R, et al. Cognition in early human immunodeficiency virus infection. Arch Neurol 1990; 47:433-440.
42. ARMY U. Army Individual Test Battery-manual of directions and scoring. Washington, DC: War Department, Adjutant General's Office, 1994.
43. Heaton R, Grant I, Matthews C. Comprehensive norms for an expanded Halstead-Reitan Battery: demographic corrections, research findings, and clinical applications. Odessa, FL: Psychological Assessment Resources, Inc., 1991.
44. Heaton RK, Taylor MJ, Manly JJ. Demographic effects and use of demographically corrected norms with the WAIS-III and WMS-III. In: Ledbetter M, ed. Clinical interpretation of the WAIS-III and WMS-III. San Diego: Academic Press, 2002.
45. Corporation P, ed. Wechsler Adult Intelligence Scale. 3rd ed (WAIS-III). San Antonio, TX: The Psychological Corporation, 1997.
46. Rey A. L'examen psychologique dans les cas d'encephalopathie traumatique. Arch Psychol 1941;28:286-340.
47. Benedict RH, Schretlen D, Groninger L, et al. Hopkins Verbal Learning Test-Revised: normative data and analysis of interform and test-retest reliability. Clin Neuropsychol 1998;12: 43-55.
48. Benedict R. Brief Visuospatial Memory Test-Revised. Odessa, FL: Psychological Assessments Resources, Inc., 1997.
49. Wechsler D. Wechsler Memory Scale-Revised. San Antonio: The Psychological Corporation, 1987.
50. Klove H. Clinical neuropsychology. In: Forster F, ed. Medical Clinics of North America. New York: Saunders, 1963.
51. Gladsjo JA, Schuman CC, Evans JD, et al. Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment 1999;6:147-178.
52. Benton A, Hamsher K, Sivan A. Multilingual Aphasia Examination. Iowa City, IA: AJA Associates, 1994.
53. Gronwall DM. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills 1977;44: 367-373.
54. Diehr MC, Heaton RK, Miller W, et al. The Paced Auditory Serial Addition Task (PASAT): norms for age, education, and ethnicity. Assessment 1998;5:375-387.
55. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: The Psychological Corporation, 1981.
56. Golden C. Stroop Color and Word test. Chicago: Stoelting, 1978.
57. Kongs S, Thompson L, Iverson G, et al. Wisconsin Card Sorting Test-64 card computerized version. Odessa, FL: Psychological Assessment Resources, Inc., 2000.
58. Reitan R, Wolson D. The Halstead-Reitan Neuropsychological Test Battery. 2nd ed. Tuscon, AZ: Neuropsychology Press, 1993.